. Bibliographie-[abrahamyan, Alternative designs for clinical trials in rare diseases, American Journal of Medical Genetics Part C : Seminars in Medical Genetics, vol.172, issue.4, p.43, 2016.

. Abrahamyan, Survival distributions impact the power of randomized placebophase design and parallel groups randomized clinical trials, Journal of Clinical Epidemiology, vol.64, issue.3, p.34, 2011.

A. , Combining expert opinions in prior elicitation, Bayesian Analysis, vol.7, issue.3, p.57, 2012.

G. Apostolakis, Bayesian Methods in Risk Assessment, Advances in Nuclear Science and Technology, pp.415-465, 1981.

J. K. Aronson, Biomarkers and surrogate endpoints, British Journal of Clinical Pharmacology, vol.59, issue.5, p.44, 2005.

B. M. Ayyub, Methods for Expert-Opinion Elicitation of Probabilities and Consequences for Corps Facilities, vol.57, p.101, 2000.

. Berger, J. O. Berger, and J. O. Berger, Prior information and subjective probability, Statistical Decision Theory and Bayesian Analysis, vol.66, p.63, 1985.
DOI : 10.1007/978-1-4757-1727-3_3

J. A. Bibliographie-[berlin-;-berlin, N-of-1 clinical trials should be incorporated into clinical practice, Journal of Clinical Epidemiology, vol.63, issue.12, p.43, 2006.

[. Billingham, Small sample sizes in clinical trials : a statistician's perspective, Clinical Investigation, vol.2, issue.7, pp.79-80, 2012.
DOI : 10.4155/cli.12.62

. Brookes, Subgroup analyses in randomised controlled trials : quantifying the risks of false-positives and false-negatives. Health Technology Assessment, vol.5, p.43, 2001.

[. Brophy, Evidence for use of coronary stents. a hierarchical bayesian meta-analysis, Annals of Internal Medicine, vol.138, issue.10, pp.777-786, 2003.

M. Brunelli, Priority vector and consistency, Introduction to the Analytic Hierarchy Process, SpringerBriefs in Operations Research, pp.17-31, 2015.
DOI : 10.1007/978-3-319-12502-2_2

, , vol.88, p.97

B. M. Buckley, Clinical trials of orphan medicines, The Lancet, vol.371, issue.9629, pp.51-77, 2008.
DOI : 10.1016/s0140-6736(08)60876-4

P. R. Burton, Helping doctors to draw appropriate inferences from the analysis of medical studies, Statistics in Medicine, vol.13, issue.17, p.80, 1994.

[. Caporali, Prednisone plus methotrexate for polymyalgia rheumatica : a randomized, double-blind, placebo-controlled trial, Annals of Internal Medicine, vol.141, issue.7, p.145, 2004.
DOI : 10.7326/0003-4819-141-7-200410050-00005

[. Cepeda, Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders, American journal of epidemiology, vol.158, issue.3, p.45, 2003.

R. Chaloner, K. Chaloner, and F. S. Rhame, Quantifying and documenting prior beliefs in clinical trials, Statistics in medicine, vol.20, issue.4, p.110, 2001.

, Bibliographie 179

[. Choy, Elicitation by design in ecology : using expert opinion to inform priors for bayesian statistical models, Ecology, vol.90, issue.1, p.99, 2009.

C. E. Clarke, Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed ? Movement Disorders, vol.23, p.24, 2008.

[. Cole, Reducing selection bias in case-control studies from rare disease registries, Orphanet Journal of Rare Diseases, vol.6, pp.61-105, 2011.

R. M. Cooke, Experts in Uncertainty : Opinion and Subjective Probability in Science, vol.2, pp.102-103, 1991.

[. Cornu, Experimental designs for small randomised clinical trials : an algorithm for choice, Orphanet Journal of Rare Diseases, vol.8, p.31, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-00818031

G. B. Crawford, The geometric mean procedure for estimating the scale of a judgement matrix, Mathematical Modelling, vol.9, issue.3, p.88, 1987.

D. Agostino and R. B. , The delayed start study design, New England Journal of Medicine, vol.361, issue.13, pp.25-26, 2009.

[. David, J. Spiegelhalter-;-david, J. Spiegelhalter, K. R. Abrams, and J. P. , Bayesian approaches to clinical trials and health-care evaluation, vol.3, p.81, 2003.

. Edwards, Why "underpowered" trials are not necessarily unethical, Lancet, vol.350, issue.9080, p.45, 1997.
DOI : 10.1016/s0140-6736(97)02290-3

, Efficiency of plasma exchange in Guillain-Barré syndrome : role of replacement fluids. French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome, Annals of Neurology, vol.22, issue.6, p.73, 1987.

B. Efron, Forcing a sequential experiment to be balanced, Biometrika, vol.58, issue.3, p.39, 1971.

. Epstein, M. A. Sladky-;-epstein, and J. T. Sladky, The role of plasmapheresis in childhood Guillain-Barré syndrome, Annals of Neurology, vol.28, issue.1, p.74, 1990.

. Bibliographie-[feldman, The randomized placebo-phase design for clinical trials, Journal of Clinical Epidemiology, vol.54, issue.6, p.33, 2001.

P. Fleming, T. R. Fleming, and J. H. Powers, Biomarkers and surrogate endpoints in clinical trials, Statistics in Medicine, vol.31, issue.25, p.44, 2012.

P. R. Freeman, The performance of the two-stage analysis of two-treatment, two-period crossover trials, Statistics in Medicine, vol.8, issue.12, p.27, 1989.

O. Fumika, A literature review on the use of expert opinion in probabilistic risk analysis, pp.102-103, 2004.

[. Gagne, Innovative research methods for studying treatments for rare diseases : methodological review, BMJ, vol.349, pp.6802-6847, 2014.

[. Gallin, The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results, New England Journal of Medicine, vol.348, issue.24, pp.200-245, 1994.

. Goodman, S. N. Sladky-;-goodman, and J. T. Sladky, A bayesian approach to randomized controlled trials in children utilizing information from adults : the case of Guillain-Barre, Clinical Trials, vol.2, issue.4, p.81, 2005.

[. Graf, Outcome in severe pediatric Guillain-Barré syndrome after immunotherapy or supportive care, Neurology, vol.52, issue.7, pp.1494-1497, 1999.

J. B. Greenhouse and H. Seltman, Using prior distributions to synthesize historical evidence : comments on the Goodman-Sladky case study IVIg in Guillain-Barré syndrome, Clinical Trials, vol.2, issue.4, p.47, 2005.

[. Griggs, Clinical research for rare disease : Opportunities, challenges, and solutions. Molecular genetics and metabolism, vol.96, pp.26-31, 2009.

[. Gsteiger, Using historical control information for the design and analysis of clinical trials with overdispersed count data, Statistics in Medicine, vol.32, issue.21, pp.3609-3622, 2013.

[. Gupta, A framework for applying unfamiliar trial designs in studies of rare diseases, Journal of Clinical Epidemiology, vol.64, issue.10, pp.26-27, 2011.

S. D. Halpern, The continuing unethical conduct of underpowered clinical trials, JAMA, vol.288, issue.3, p.46, 2002.

. Hampson, Bayesian methods for the design and interpretation of clinical trials in very rare diseases, Statistics in Medicine, vol.33, issue.24, p.115, 2014.

[. Hoffman, A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis, and International Network for the Study of Systemic Vasculitides, vol.46, pp.1309-1318, 2002.

R. Hu, F. Hu, and W. F. Rosenberger, The Theory of Response-Adaptive Randomization in Clinical Trials, GoogleBooks-ID : CmkFQ2Qibk8C. 2 citations pages, pp.36-37, 2006.

M. D. Hughes, Reporting Bayesian analyses of clinical trials, Statistics in Medicine, vol.12, issue.18, p.80, 1993.

A. Ishizaka and A. Labib, Analytic hierarchy process and expert choice : Benefits and limitations, OR Insight, vol.22, issue.4, p.97, 2009.

[. Jansen, Guillain-Barré syndrome in childhood : natural course and efficacy of plasmapheresis, Pediatric Neurology, vol.9, issue.1, pp.16-20, 1993.

. Bibliographie-[johnson, Effect of warfarin on survival in scleroderma-associated pulmonary arterial hypertension (ssc-pah) and idiopathic pah. belief elicitation for bayesian priors, The Journal of rheumatology, vol.38, issue.3, p.110, 2011.

[. Jover, Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial, The Clinical Journal of Pain, vol.134, issue.2, p.32, 2001.

[. Khatri, Plasmapheresis with acute inflammatory polyneuropathy, Pediatric Neurology, vol.6, issue.1, pp.17-19, 1990.

T. R. Knapp, The overemphasis on power analysis. Nursing Research, vol.45, p.45, 1996.

W. W. Koczkodaj, A new definition of consistency of pairwise comparisons, Mathematical and Computer Modelling, vol.18, issue.7, p.94, 1993.

M. Korinthenberg, R. Korinthenberg, and J. S. Mönting, Natural history and treatment effects in Guillain-Barré syndrome : a multicentre study, Archives of Disease in Childhood, vol.74, issue.4, pp.281-287, 1996.

S. W. Lagakos, Clinical trials and rare diseases, The New England Journal of Medicine, vol.348, issue.24, p.26, 2003.

[. Lamont, Plasmapheresis in children with Guillain-Barré syndrome, Neurology, vol.41, issue.12, p.74, 1991.

[. Lilford, Clinical trials and rare diseases : a way out of a conundrum, Bmj, vol.311, issue.7020, p.79, 1995.

[. Lillie, The n-of-1 clinical trial : the ultimate strategy for individualizing medicine ? Personalized medicine, vol.8, p.30, 2011.

. Liu-seifert, Delayed-start analysis : Mild alzheimer's disease patients in solanezumab trials, 3.5 years, Alzheimer's & Dementia : Translational Research & Clinical Interventions, vol.1, issue.2, pp.24-25, 2015.

M. Maclure, The case-crossover design : a method for studying transient effects on the risk of acute events, American Journal of Epidemiology, vol.133, issue.2, pp.26-27, 1991.

. Mahajan, R. Gupta-;-mahajan, and K. Gupta, Adaptive design clinical trials : Methodology, challenges and prospect, Indian Journal of Pharmacology, vol.42, issue.4, p.35, 2010.

C. J. Mann, Observational research methods. research design ii : cohort, cross sectional, and case-control studies, Emergency Medicine Journal, vol.20, issue.1, p.26, 2003.

M. D. and R. J. , Special study designs : early escape, enrichment, studies in non-responders, Communications in Statistics-Theory and Methods, vol.23, issue.2, p.33, 1994.

. Morita, and MÃÂ 1 4 ller, 2008.

M. Nason, D. Follmann, and . Neuenschwander, Design and analysis of crossover trials for absorbing binary endpoints, Clinical Trials, vol.64, issue.2, pp.72-118, 2010.

. Nony, A methodological framework for drug development in rare diseases, Orphanet Journal of Rare Diseases, vol.9, p.31, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01097224

. O'hagan, Uncertain judgements : Eliciting experts probabilities. 4 citations pages, vol.102, p.105, 2006.

[. Olanow, A double184 Bibliographie blind, delayed-start trial of rasagiline in parkinson's disease, New England Journal of Medicine, vol.361, issue.13, pp.1268-1278, 2009.

[. Paradiso, Epidemiological, clinical, and electrodiagnostic findings in childhood Guillain-Barré syndrome : a reappraisal, Annals of Neurology, vol.46, issue.5, pp.701-707, 1999.

, Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group, Cité page 26 [Plasma, 1997] Plasma, vol.61, p.73, 1997.

, Plasmapheresis and acute Guillain-Barré syndrome. The Guillain-Barré syndrome Study Group, Neurology, vol.35, issue.8, p.73, 1985.

S. J. Pocock and R. Simon, Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial, Biometrics, vol.31, issue.1, p.40, 1975.

[. Pöyhönen, An experiment on the numerical modelling of verbal ratio statements, Journal of Multi-Criteria Decision Analysis, vol.6, issue.1, p.95, 1997.

[. Rahme, Bayesian sample size determination for estimating binomial parameters from data subject to misclassification, Journal of the Royal Statistical Society : Series C (Applied Statistics), vol.49, issue.1, p.85, 2000.

C. P. Robert, The Bayesian Choice. Springer Texts in Statistics, vol.3, p.66, 2007.

R. ;. Rosenbaum, P. R. Rosenbaum, and D. B. Rubin, The central role of the propensity score in observational studies for causal effects, Biometrika, vol.70, issue.1, p.45, 1983.

W. F. Rosenberger and J. M. Lachin, Randomization in clinical trials : Theory and practice, p.38, 2016.

R. W. Saaty, The analytic hierarchy process-what it is and how it is used, Mathematical Modelling, vol.9, issue.3, p.98, 1987.

, Bibliographie 185

T. L. Saaty, A scaling method for priorities in hierarchical structures, Journal of Mathematical Psychology, vol.15, issue.3, p.93, 1977.

T. L. Saaty and G. Hu, Ranking by eigenvector versus other methods in the analytic hierarchy process, Applied Mathematics Letters, vol.11, issue.4, p.87, 1998.

. Saaty, T. L. Vargas-;-saaty, and L. G. Vargas, Comparison of eigenvalue, logarithmic least squares and least squares methods in estimating ratios, Mathematical Modelling, vol.5, issue.5, pp.87-93, 1984.

F. J. Samaniego, A Comparison of the Bayesian and Frequentist Approaches to Estimation, Springer Science & Business Media. Google-Books-ID : WGaKMfKm0sAC. Cité page, p.53, 2010.

B. Sándor, Solution of the least squares method problem of pairwise comparison matrices, Central European Journal of Operations Research, vol.16, issue.4, 2008.

[. Schmidli, The network meta-analytic-predictive approach to non-inferiority trials, Statistical Methods in Medical Research, vol.22, issue.2, pp.219-240, 2013.

S. Senn, Cross-over trials in statistics in medicine : the first 25 years, Statistics in Medicine, vol.25, issue.20, p.27, 2006.

S. L. Shook, The randomized placebo-phase design : Evaluation, interim monitoring and analysis, p.34, 2010.

R. J. Simes, Prospective meta-analysis of cholesterol-lowering studies : the prospectivepravastatin pooling (ppp) project and the cholesterol treatment trialists (ctt) collaboration, The American Journal of Cardiology, vol.76, issue.9, p.45, 1995.

[. Spiera, A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA), Clinical and Experimental Rheumatology, vol.19, issue.5, p.133, 2001.

[. Straube, Enriched enrolment : definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review, British Journal of Clinical Pharmacology, vol.66, issue.2, p.32, 2008.

P. Sun and L. P. Garrison, Retrospective outcomes studies for orphan diseases : challenges and opportunities, Current Medical Research & Opinion, vol.28, issue.4, p.44, 2012.

[. Taji, K. Matsumoto-;-taji, and K. Matsumoto, Inverse sensitive analysis of pairwise comparison matrices, Journal of the Operations Research Society of Japan, vol.49, issue.4, p.94, 2006.

[. Tan, Strategy for randomised clinical trials in rare cancers, BMJ, vol.327, issue.7405, p.80, 2003.

[. Tan, Strategy for randomised clinical trials in rare cancers, BMJ, vol.327, issue.7405, p.72, 2003.

[. Tan, Can external and subjective information ever be used to reduce the size of randomised controlled trials ?, Contemporary Clinical Trials, vol.29, issue.2, p.85, 1927.

F. G. Van-der-meché and P. I. Schmitz, A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group, vol.326, p.73, 1992.

L. J. Wei, The adaptive biased coin design for sequential experiments, The Annals of Statistics, vol.6, issue.1, p.39, 1978.

[. Wei, K-treatment comparisons with restricted randomization rules in clinical trials, The Annals of Statistics, vol.14, issue.1, p.39, 1986.

. Wellek, S. Blettner-;-wellek, and M. Blettner, On the proper use of the crossover design in clinical trials, Deutsches Arzteblatt International, vol.109, issue.15, pp.27-28, 2012.

[. Zucker, Individual (N-of-1) trials can be combined to give population comparative treatment effect estimates : Methodologic considerations, Journal of clinical epidemiology, vol.63, issue.12, p.30, 2010.